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Biotin feeding in a Balb/c mouse model of breast cancer suggest that the tumor load is 
~100% greater in biotin-deficient mice compared with biotin-sufficient controls, and that 
the increase is associated with metastasis rather than new tumors. The oncogenes c-Myc 
and COX-2 are implicated in cancer metastasis, and their expressions are repressed by 
binding of MBP-1 to the promoter. Mass spectrometry studies, designed to discover 
novel biotin-containing proteins, suggest that lysine residues K10 and K12 in the c-Myc 
promoter binding protein (MBP-1) contains covalently bound biotin (MBP-1bio). We 
hypothesized that biotinylation of MBP-1 increases the binding of MBP-1 to the c-Myc 
and COX-2 promoter, thereby decreasing oncogene expression and metastasis. A novel 
antibody against MBP-1bio was used to confirm the existence of MBP-1bio in human 
mammary carcinoma MCF-7 cells; the abundance of MBP-1bio depended on the 
concentration of biotin in culture media: supplemented > sufficient > deficient. The 
activity of a c-Myc reporter gene was ~37% greater in biotin-deficient cells compared 
with sufficient and supplemented controls. Likewise, both c-Myc and COX-2 mRNA 
levels were significantly increased in deficient compared with sufficient cells. When K10 
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and K12 in MBP-1 were removed by site-directed mutagenesis, biotin supply no longer 
affected the expression of c-Myc and COX-2 in MCF-7 cells. Biotinylation of MBP-1 is 
an enzymatic process catalyzed by using recombinant holocarboxylase synthetase 
(HLCS), judged by using recombinant HLCS and recombinant MBP-1. Consistent with 
this observation, c-Myc and COX-2 are de-repressed in HLCS mutant WG2215 human 
fibroblasts compared with controls. We conclude that loss of MBP-1bio in biotin-
depleted and HLCS-deficient organisms leads to an increased expression of oncogenes, 
thereby increasing cancer risk. 
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Biotin, Holocarboxylase Synthetase (HLCS) and biotinylation 
 
Biotin (C10H16N2O3S, MW: 244.31064), known as vitamin B7 or H, is a water-soluble 
vitamin involved in epigenetic regulations and many metabolic pathways in mammals (1-
7). Biotin is a monocarboxylic acid contains an ureido group, thiophane heterocyclic ring, 
and a valeric acid side chain (7-9) (Fig. 1). 
 
 
 
Figure 1. 2D structure of biotin (Pubchem CID 171548). 
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Biotin is found in high concentration in varieties of foods including egg yolk, cow milk, 
liver and some vegetables in the form of free biotin or biotin-binding protein conjugates 
(10). For uptake of biotin from dietary resource, the biotin-binding proteins are converted 
to free biotin by gastrointestinal proteases, peptidases, and biotinidase (7). The 
fundamental metabolic role of biotinidase (BTD) is to hydrolyze biocytin generated in the 
breakdown of biotin-binding carboxylases (11). Therefore, free biotin is released and 
recycled in holocarboxylase synthesis and used as co-factor in epigenetic and metabolic 
processes (9). The transportation of free biotin to the cells is depended on the sodium-
dependent multi-vitamin transporter (SMVT) (12). It has been reported that 
monocarboxylate transporter 1 (MCT1) is also involved in cellar biotin transportation in 
peripheral blood mononuclear cells (11, 13, 14) (Fig. 2). 
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Figure 2. Biotin transport and metabolism, taken from (15). ACC1: 
cytoplasmatic acetyl-CoA carboxylase alpha, ACC2: mitochondrial acetyl-
CoA carboxylase beta, B: biotin, MCC: and 3- methylcrotonyl-CoA 
carboxylase, MCT1: monocarboxylate transporter 1, PC: pyruvate 
carboxylase, PCC: propionyl- CoA carboxylase, SMVT: sodium 
multivitamin transporter.  
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Holocarboxylase synthetase (HLCS), a 726 amino acids protein, is the sole biotin protein 
ligase in the human proteome and is responsible for catalyzing biotinylation of acetyl-
CoA caboxylase1 and 2 (ACC1, ACC2), 3-methylcrotonyl-CoA carboxylase (MCC), 
pyruvate carboxylase (PCC) and propionyl-CoA carboxylase (PCC) and other proteins 
(16). Biotinylated carboxylases are localized to cytoplasm and mitochondria and play 
roles in intermediary metabolism including fatty acid synthesis, regulation of fatty acid 
catabolism, elimination of odd-chain fatty acids, leucine metabolism, and 
gluconeogenesis (1-3, 5, 6, 17, 18). HLCS also enters the nuclear compartment (2, 19-21). 
Nuclear HLCS orchestrates the assembly of a multiprotein gene repression complex (22, 
23). The formation of the multiprotein complex depends on the availability of biotin; the 
complex appears to play an important roles in the repression of long terminal repeats 
(LTRs), thereby contributing to genome stability (24). The covalent binding of biotin to 
histones (1) appears to be a mere side effect of the close physical proximity of HLCS and 
histones (22, 23)
7 
 
 
c-Myc promoter binding protein (MBP-1) and target 
oncogenes of MBP-1 repression 
 
c-Myc promoter binding protein (MBP-1, NCBI Reference Sequence: NM_001201483.1) 
is a transcriptional variant encoded by ENO1 enolase 1, (alpha) [Homo sapiens](25) 
(Gene ID: 2023). This MBP-1 protein consists of 341 amino acids is localized to the 
nucleus that functions as a novel transcriptional repressor of oncogene c-Myc through 
binding to the TATA box of its P2 promoter (26-28). In addition to c-Myc, MBP-1 also 
represses the oncogenes cyclooxygenase-2 (COX-2) and ERBB2 (26, 29, 30). The MBP-
1 N-terminus is crucial for oncogene repression, which also involves accessory factors 
such as activated Notch1 receptor, Kelch protein NS1-BP, and histone deacetylases (31-
34). C-Myc, COX-2, and ERBB2 are associated with tumorigenesis including breast and 
gastric cancer, and low levels of MBP-1 have been observed in invasive ductal breast 
carcinoma (IDC), which supporting the role of MBP-1 as a potential prognostic marker in 
carcinoma (29, 35, 36). 
c-Myc, Cox-2, and ERBB2 are examples of oncogenes regulated by MBP-1. c-Myc 
dimerizes with Max; the heterodimer binds to E boxes in target genes and causes 
aberrations in cell cycle, growth, apoptosis and metabolism (37-39) ( Fig. 3). 
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Figure 3. Mechanisms of c-Myc involved in gene transcription, cell 
growth and proliferation. 
COX-2 is the inducible isoform of the COX-2/PTGS2 gene encoding prostaglandin-
endoperoxide synthase 2 (PTGS2, Gene ID: 5743), which is the key enzyme in 
prostaglandin biosynthesis. High levels of COX-2 have been observed in tumor tissues 
from a breast cancer mouse model housed in standard environment (40). Strong 
associations between COX-2 and breast or gastric cancer have been established, COX-2 
dependent activation of the p38/MAPK pathway (41), Jun N-terminal kinases mediated 
activation of cell invasion in MCF-7 cells (42), and IL-1beta and NFkappaB mediated 
induction of inflammation (43). COX-2 inhibitors such as celecoxib are considered 
promising agents in the treatment and prevention of breast cancer (44, 45).   
ERBB2 (Gene ID: 2064) encodes a member of the epidermal growth factor (EGF) 
receptor family of receptor tyrosine kinases. High levels of ERBB2 have been observed 
in metastatic breast cancer. ERBB2 contributes breast cancer metastasis through 
increased expression of glutaminase 1(36), activation of NF-kappaB (46), and increased 
breast cancer cell migration and invasion (47). 
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In conclusion, MBP-1 is an important repressor of three oncogenes that play crucial roles 
in tumorigenesis in human prostate, gastric and breast cancer. 
 
 
CHAPTER 2 
BIOTINYLATION OF THE C-MYC PROMOTER 
BINDING PROTEIN MBP-1 DECREASES C-MYC 
AND COX-2 EXPRESSION IN HUMAN 
MAMMARY CARCINOMA MCF-7 CELLS 
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Introduction 
The c-Myc promoter binding protein, MBP-1, is encoded by the Enolase-1 gene and 
consists of 341 amino acids. MBP-1 localizes in the cell nucleus and functions as a 
transcriptional repressor of the oncogenes c-Myc, cyclooxygenase-2 (COX-2), and 
ERBB2 (26-30, 48, 49). The N-terminus in MBP-1 is essential for repressor activity (31). 
Repression may involve accessory factors such as Notch1 receptor (32), Kelch protein 
NS1-BP (33), histone deacetylases (34), and miR-29b (50).   
Recently, our discovery-based LC/MS/MS analysis identified MBP-1 as one of 108 novel 
biotin-containing proteins in human embryonic kidney HEK293 cells (Li Y. et al., 
submitted). There is precedence that posttranslational modifications affect the activity of 
transcription factors. For example, biotin supplementation decreases Sp1 and NF-κB 
binding to their response elements (51); HLCS-dependent biotinylation of HSP72 
increases RANTES expression(52). Importantly, at the time we had completed a biotin 
feeding study in a murine breast cancer model, which suggested that the tumor load 
increases by about 100% in biotin-deficient mice compared with biotin-sufficient and 
biotin-supplemented mice (see Results). Based on the roles of MBP-1 in oncogene 
repression, the detection of biotinylated MBP-1 by mass spectrometry, and the 
observations in biotin feeding studies, we hypothesized that the binding of biotin to 
MBP-1 increases oncogene repressor activity. We further hypothesized that biotinylation 
of MBP-1 is mediated by the sole biotin protein ligase in the human proteome, 
holocarboxylase synthetase (HLCS) (16). 
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Materials and Methods 
 
Cell cultures 
 
Human embryonic kidney HEK293 cells (American Type Culture Collection, CRL-1573) 
were cultured in Dulbecco's Modified Eagle Medium (DMEM) media containing 10% 
fetal bovine serum, penicillin, streptomycin, and L-glutamine as described previously 
(53).Human mammary carcinoma MCF-7 cells were cultured in DMEM/Nutrient F-12 
Ham (DMEM/F12). In select experiments, MCF-7 cells were cultured in biotin-defined 
DMEM, prepared as described previously (53). Biotin-defined media contained the 
following levels of biotin: 0.025 nmol/L, 0.25 nmol/L, and 10 nmol/L, representing biotin 
plasma levels observed in deficient, normal, and supplemented persons, respectively (11, 
53, 54). HLCS-deficient WG2215 fibroblasts from an HLCS mutant patient (Montreal 
Children’s Hospital Cell Repository, Montreal, Canada) and HLCS wild-type human 
neonatal normal dermal fibroblast (American Type Culture Collection, PCS-201-010) 
were cultured in Fibroblast Basal Medium supplemented with 2% fetal bovine serum, 5 
ng/mL recombinant human fibroblast growth factor (rh FGF) beta, 5 µg/mL recombinant 
human insulin, 1 µg/mL hydrocortisone, 50 µg/mL ascorbic acid, and 7.5 mM L-
glutamine. 
 
Purification of biotinylated proteins and mass spectrometry 
analysis 
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Whole protein extracts were prepared from HEK293 cells using ice-cold BugBuster
®
 
Protein Extraction Reagent (Novagen, EMD Millipore), protease inhibitor cocktail 
(Sigma). Biotin-containing proteins were purified using a Monomeric Avidin Agarose 
following the manufacturer’s recommendations (Thermo Scientific; biotin-binding 
capacity=1.2 mg biotinylated protein/mL settled resin)  (Fig. 1). 
Biotinylated proteins were resolved by gel electrophoresis and cut-out bands were 
digested with trypsin (55). Biotinylated proteins and biotinylation sites were identified by 
LC/MS/MS in the mass spectrometry core facility in the Redox Biology Center at the 
University of Nebraska-Lincoln. The acquired spectrum was compared to the human 
reference proteome for sequence identification using the MASCOT database analysis 
software (56). 
 
Plasmids and recombinant proteins 
The c-Myc promoter luciferase reporter plasmid, Luc-SNM, includes base pairs -467 to 
+36 in the human c-Myc gene and two MBP-1 binding sites (57); the plasmid was 
generously provided by Dr. Mark D Minden in the Department of Cellular and Molecular 
Biology, Ontario Cancer Institute, Toronto, Canada. 
Full-length human MBP-1 (Genbank NM_001201483.1) was cloned using a human 
enolase 1 (alpha) cDNA clone (MGC: 17252; IMAGE: 3447583) using forward primer 
5’- TTCGGGTAG TGGAAAACCAG-3’ and reverse primer 5’- CAGCAGCTCGAATT 
TCTTCC - 3’; the PCR product was ligated into vector pET28a+ (Novagen) using 
FastDigest BamHI and SalI (Thermo Scientific), thereby creating plasmid 
pET28a+_MBP-1 for preparing recombinant MBP-1. Recombinant his-tagged MBP-1 
16 
 
 
was expressed and purified as described previously (1). Our previous studies suggest that 
BirA in E. coli catalyzes the binding of biotin to some recombinant proteins (58); 
biotinylated recombinant MBP-1 was removed by avidin chromatography (not shown). 
Lysine residues K10 and K12 were identified as targets for biotinylation (see Results). 
Site-directed mutagenesis was used to create a plasmid in which arginines were 
substituted for K10 and K12.  Mutant MBP-1 was created using MGC clone 17252, the 
GeneTailorTM Site-Directed Mutagenesis System (Invitrogen), and primers 
ATGGAACAGAAAATAGATCTAGGTTTG GTGCGAACGC and 
GCGTTCGCACCAAACCTAGATCTATTTTCTGTTCCAT. The plasmid was denoted 
ENO_Mut. The plasmid was digested with Fastdigest EcoRI and KpnI and ligated into 
the p3XFLAG-Myc-CMVTM-26 expression vector (Sigma-Aldrich) to create plasmid 
MBP-1R10,R12 coding for a Flag-tagged MBP-1protein. 
Plasmid Flag-MBP-WT and MBP-1R10,R12 for expression of FLAG-tagged recombinant 
wild-type and mutant MBP-1, respectively, were created as described for 
pET28a+_MBP-1, using forward primer 5’- ACAGGCTTCCATTGACCAG -3’ and 
reverse primer 5’- TCACCATAGAGTGCTTCCAAC - 3’. Plasmid C7472-CMV-7-BAP 
codes for FLAG (Sigma-Aldrich) and was used as control. 
GST-tagged recombinant full-length HLCS was prepared by using plasmid pET41a (+)-
HLCS as described previously (1). The identities of all plasmids were verified by 
sequencing. 
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Generation of Anti–MBP-1 Antibody and Dot-blot Assay 
The following synthetic, MBP-1 based peptide was used to raise antibodies against MBP-
1, biotinylated at K10 and K12 (MBP-1bio), as described previously (3): ac-
CZIEMDGTENK(bio)SK(bio)FGANA-NH2 (Cocalico Biologicals, Inc., PA).  
Antibody specificity was assessed using dot blot analysis. Briefly, dilution series (1.5 ug, 
0.75 ug and 0.375 ug) of the following peptides were spotted onto PVDF membranes, air 
dried, and probed with anti-MBP-1bio and goat anti-rabbit IgG：synthetic K10, K12-
biotinylated MBP-1( MBP-1bio), synthetic unbiotinylated MBP-1, chemically 
biotinylated bovine serum albumin (BSAbio), synthetic peptides mimicking K18- and 
K8-biotinylated histones H3 (H3K18bio) and H4 (H4K8bio). 
 
Western Blot Analysis 
Proteins were extracted from MCF-7 cells as described above; equal amount of protein 
(~30 μg) were resolved by gel electrophoresis, and transblots were probed with the 
following antibodies at 4°C overnight: anti-MBP-1bio, anti-Anti-6X His tag (Origene) 
and anti- GAPDH (Santa Cruz Biotechnology). Secondary antibodies and visualization 
and quantification by infrared imaging were conducted as described previously (59). 
Blots were revealed and quantitated by Odyssey Infrared Imaging System (LI-COR 
Biosciences). 
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In vitro biotinylation assay 
His-tagged MBP-1 was incubated with GST-tagged HLCS as described previously (1). 
Biotin bound to MBP-1 was probed using streptavidin (1). Anti-His and Coomassie Blue 
were used to confirm equal loading. 
 
Transfection and luciferase assay 
These assays were conducted to assess whether mutation of K10 and K12 in MBP-1 
disrupts the regulation of MBP-1 repressor activity by biotin supply. Briefly, MCF-7 cells 
were with Flag-WT-MBP1, MBP-1R10,12R, or C7472-CMV-7-BAP (control) using 
TurboFect (Thermo Scientific) following the manufacturer's instructions (about 2 μg 
plasmid/1,000,000 cells). Forty-eight hours after transfection, the expression of c-Myc 
and COX-2 were analyzed using qRT-PCR. 
MCF-7 cells cultured in biotin-defined media were cotransfected with luciferase reporter 
Luc-SNM (pGL2 basic vector as control) and beta-galactosidase internal control vector 
using TurboFect (Thermo Scientific) following the manufacturer's instructions (about 2 
μg plasmid/1,000,000 cells).  Forty-eight hours after transfection, cells were harvested for 
the quantification of luciferase and beta-Gal activities according to standard methods 
(Promega). Luciferase activity was measured by subtracting machine background and 
normalizing via beta-galactosidase activity. The results are the average of at least three 
independent experiments. 
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Real-Time PCR Analysis (qRT-PCR) 
Total RNA was isolated from MCF-7 cells using the illustra RNAspin Mini Kit (GE 
Healthcare Life Sciences) and reverse transcribed into cDNA using the ImProm-II™ 
Reverse Transcription System (Promega) following the manufacturer's protocol. The 
abundance of transcripts coding for human c-Myc, COX-2, HLCS and GAPDH (control) 
were quantified by using Power SYBR Green PCR Master Mix (Applied Biosystems) 
and the following primers: human c-Myc, 5’- TTCGGGTAGTGGAAAACCAG -3’ 
(forward) and 5’-CAGCAGCTCGAATTTCT TCC -3’ (reverse); human COX-2, 5’- 
ACAGGCTTCCATTGACCAG-3’ (forward), 5’- TCACCATAG AGTGCTTCCAAC-3’ 
(reverse); HLCS, 5’- TGAGACCTGATCCTTAACTTCC -3’ (forward) 5’-
ATGGAAGATAGACTC CACAT -3’ (reverse); GAPDH (control), 5’- 
TCCACTGGCGTCT TCACC -3’ (forward), 5’- GGCAGAGAT GATGACCCTTT -3’ 
(reverse). Transcript abundance was quantified using the comparative threshold cycle (Ct) 
method. 
 
Statistical Analysis 
 
Homogeneous variances were analyzed by using Bartlett’s test. Significance of 
differences was tested by one-way ANOVA and the Fisher's Protected Least Significant 
Difference (PLSD). For pairwise comparisons the t-test was used. StatView5.0.1 (SAS 
Institute) was used to perform all calculations. Data were reported as mean ± SD. 
Differences were considered significant if P < 0.05.
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Results 
 
Discovery of novel biotinylated proteins in HEK293 cells 
 
Analysis of protein extracts by LC/MS/MS revealed the identities of 108 novel 
biotinylated proteins in human cells (Li Y. et al., in preparation), including biotinylation 
of K10 and K12 in the N-terminus of MBP-1  (Fig. 1). 
We raised anti-MBP-1bio to determine whether MBP-1bio is detectable in using western 
blot analysis and to assess whether the abundance of MBP-1bio depends on the levels of 
biotin in culture media. Anti-MBP-1bio produced a strong signal with peptide MBP-1bio, 
but did not cross-react to a meaningful extent with unbiotinylated MBP-1, chemically 
biotinylated bovine serum albumin (BSAbio), synthetic peptides mimicking K18- and 
K8-biotinylated histones H3 (H3K18bio) and H4 (H4K8bio) (Fig. 2A). Pre-immune 
serum produced negligible signal with biotinylated MBP-1 and other controls (Fig. 2B). 
Equal loading was confirmed using Ponceau S stain as probe (not shown). The signal 
intensity produced by MBP-1bio was about 40 times greater than that produced by 
unbiotinylated MBP-1 (Fig. 2C). Pre-immune serum produced negligible signal 
compared with anti-MBP1bio, when MCF7 cell extracts were assayed using western blot 
analysis (Fig. 2D). 
After 3 days of culture in biotin-defined media, the abundance of MBP-1bio in biotin 
sufficient MCF-7 cells was increased, compared with that of deficient and physiological 
cells (Fig. 3A). Compared with anti-MBP-1bio, pre-immune serum produced no signal. 
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The efficacy of biotin treatment was confirmed using the abundance of bioitnylated 
carboxylases as markers for biotin status (Fig. 3B).   
 
Enzymatic biotinylation of MBP-1 
HLCS is the sole enzyme responses for catalyzing covalent binding of biotin to proteins 
in the human proteomics. To determine the biotin ligase activity of HLCS on MBP-1, the 
in vitro biotinylation assay was conducted. His-MBP1 was biotinylated in a time-
dependent manner after incubated with GST-HLCS (Fig. 4) (52). 
 
c-Myc and COX-2 expression depends on biotin supply and 
HLCS activity in MCF-7 cells 
The expression of c-Myc and COX-2 is inversely linked with biotin concentrations in 
culture media. When MCF-7 cells were culture in biotin-defined media for 3 days, the 
luciferase activity of c-Myc promoter reporter gene construct Luc-SNM (57) was 
significantly improved in deficient cells, while decreased in sufficient cells, compared 
with physiological cells (Fig.5). Following the treatment of biotin deficiency for 3 days, 
MCF-7 cells showed a strong upregulation of COX-2 (Fig.6A) and c-Myc (Fig.6B) 
mRNA expression compared with biotin treatment of physiological level. Treatment with 
biotin-supplemented media for 3 days significantly decreased c-Myc (Fig.6B) expression 
but had no effect on COX-2 (Fig.6A). 
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HLCS activity is an important factor in repressing oncogene expression, particularly that 
of COX-2. For example, the abundance of COX-2 mRNA was about 9-fold greater in 
HLCS mutant WG2215 fibroblasts compared with wild-type controls (Fig. 7A).  The 
abundance of c-Myc mRNA followed the same trend but the increase in HLCS mutant 
fibroblasts amounted to only 20% and did not reach a statistically significant level (P = 
0.071) (Fig. 7B). 
Mutagenesis studies suggest that biotinylation of K10 and K12, as opposed to 
biotinylation of other residues, is a crucial event in the repression of oncogenes. When 
MCF-7 cells were transfected with Flag constructs, the expression of COX-2 mRNA 
decreased by >50% in cells transfected with the wild-type plasmid Flag-WT-MBP1 
compared to cells transfected with the mutant plasmid MBP-1R10,12R (Fig. 8A). Not 
surprisingly, COX-2 expression was intermediate in cells transfected with the Flag-
control vector, because these cells presumably express wild-type MBP-1 from the two 
endogenous alleles; in Flag-WT-MBP1 transfectants the plasmid provides additional 
template, whereas in Flag-Mut-MBP1 transfectants mutant MBP-1 outcompetes the wilt-
type MBP-1 transcribed from the two endogenous alleles. The pattern was the same for c-
Myc (Fig. 8B) but the magnitude of effect was smaller than that observe for COX-2. 
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Figure 1. MBP-1 is a novel biotin-binding protein in HEK293 
cells. LC/MS/MS analysis suggests that K10 and K12 in MBP-1 
are biotinylated. 
24 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Generated anti-MBP-1bio specific against 
biotinylated MBP-1. (A) Anti-MBP-1bio produced a strong signal 
with peptide MBP-1bio in a dose-depend manner (1.5 ug, 0.75 ug 
and 0.375 ug). (B) No signal produced by pre-immune serum. (C) 
The signal intensity produced by 1.5 ug peptides, compared with 
that produced by unbiotinylated MBP-1. (D) Extracts of MCF-7 
cells after 3 days cultured in biotin-defined media, resolved by gel 
electrophoresis and probed with anti-MBP-1bio and pre-immune 
serum. MBP-1: synthetic unbiotinylated MBP-1 peptides; MBP-
A B 
C D 
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1bio: synthetic K10,K12-biotinylated MBP-1 peptides; BSAbio: 
chemically biotinylated bovine serum albumin; H3K18bio: 
synthetic peptides mimicking K18-biotinylated histone H3; 
H4K8bio: synthetic peptides mimicking K8-biotinylated histones 
H4. 
 
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
Figure 3.  The abundance of MBP-1 biotinylation was directly 
correlated with biotin-supply. (A) Abundance of 
biotinylated MBP-1 in MCF-7 cells after 3 days of 
culture in biotin-defined media. (B) Abundance of 
biotinylated carboxylases in MCF-7 cells after 3 days of 
culture in biotin-defined media. 
 
 
B A 
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Figure 4. MBP-1 interacts with HLCS in vitro. Recombinant 
GST-HLCS catalyzed the binding of biotin to recombinant His-
MBP-1, judged by streptavidin blots. 
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Figure 5. Biotin-supply regulates c-Myc promoter activity in 
MCF-7 cells. Luciferase activity of c-Myc promoter reporter 
construct in MCF-7 cells cultured in biotin-defined media, 
normalized by beta-galactosidase activity. 
a,b
Bars not sharing the 
same letter are significantly different;  P< 0.05; N=3. 
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Figure 6. Biotin-supply regulates COX-2 and c-Myc in MCF-7 
cells. Expression of COX-2 (A) and c-Myc (B) in MCF-7 cells 
after 3 days of culture in biotin-defined media.
a,b,c
Bars not sharing 
the same letter are significantly different;  P< 0.05; N=3. 
B A 
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Figure 7. The biotin-ligase activity of HLCS is required for 
suppressor activity of MBP-1 on COX-2 and c-Myc. Expression 
of COX-2 (A) and c-Myc (B). 
a,b
Bars not sharing the same letter 
are significantly different; P < 0.05; N=3.
A B 
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Figure 8. The repressor ability of MBP-1 was inhibited when 
the MBP-1 lacking biotinylation sites K10 and K12. 
Overexpression of wild type MBP-1 decreased COX-2 (A) and c-
Myc (B) expression.  However, the abundance of COX-2 (A) and 
c-Myc (B) were upregulated in MCF-7 cells overexpressing mutant 
MBP-1 compared with MCF-7 cells overexpressing Flag-WT-
MBP1 (N=1 with three technical replicates). 
A B 
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Discussion  
 
The novelty of  this study comes from the following points: 1）this is the first report of 
c-Myc promoter binding protein (MBP-1) biotinylation in the human proteome; 2) HLCS 
is the sole enzyme responses for catalyzing covalent binding of biotin to MBP-1, in 
addition to HSP72, carboxylases and histones (16, 52, 60); 3)  K10 and K12 residues 
located in the N-terminal functional domain of MBP-1 are the targets of biotinylation (31, 
48). 
Importantly, we showed that biotinylation of MBP-1 depends on biotin supply. We also 
provided the evidences that the abundance of MBP-1 targets c-Myc (34) and COX-2 (29), 
oncogenes strongly associate with tumorigenesis and metastasis of breast cancer (41, 61, 
62), can be regulated by biotin supply as well as in an HLCS-mediated manner. 
Combined with these observations, this study may provide insights epigenetic 
explanations of observations in our Bal b/c wild type mice biotin feeding studies, which 
suggests that biotin-deficient induced a ~100% increase in percentage of mice carry 
multiple tumors or the percentage of tumors presenting as multiple (Fig. 8). Given the 
observations of biotin deficiency increasing oncogenes c-Myc and COX-2 expression in 
vitro in this study, the increase of tumor load in biotin-deficient mice may be induced by 
improving expression of oncogenes, unregulated by lacking of MBP-1 biotinylation.  
Several uncertainties needed to be considered: 1) no human biotin requirements or foods 
intake recommendations have been estimated; 2) currently, there is no reliable marker in 
quantification of biotin status in human (63). Therefore, it is uncertain whether the biotin-
33 
 
 
dependent regulation of mechanisms contributing to tumorigenesis and is significant in 
western population. However, marginal biotin deficiency is common in pregnant women, 
which may cause human birth defects(64); biotin deficiency and low serum biotinidase 
activity can be induced by Valproic acid (VPA) treatment in human (65, 66). More 
importantly, several population-based studies reported that a substantial proportion of 
cancer patients treated with chemotherapy and radiation therapy have deficiencies of 
multiple vitamins (67-70), which suggests that biotin deficiency may be common in 
cancer patients with chemotherapy and radiation treatment. 
Collectively, the covalent binding of biotin to MBP-1 is strongly associated with 
oncogenes expression. Future studies including biotin status in cancer patients, breast 
cancer risk in HLCS knock-out mice (conditional knock-out project in progress) will be 
conducted to determine whether biotin deficiency increases metastasis, development of 
new tumors or both in breast cancer. 
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Figure 9. Tumor load of Bal b/c wild type mice in biotin-
feeding study. Both percentage of mice carry multiple tumors (A) 
and percentage of mice carrying tumors presenting as multiple (B) 
were ~100% increase in low-biotin-feeding mice compared with 
mice fed with physiological and high levels of biotin in diet.
A B 
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APPENDIX 
List of Primers 
Table 1 Human primers used for qRT-PCR 
 
Gene 
 
Primer Sequence (5’-3’) Ta (oC) 
c-Myc 
Forward TTCGGGTAGTGGAAAACCAG 
50 
Reverse CAGCAGCTCGAATTTCTTCC 
COX-2 
Forward ACAGGCTTCCATTGACCAG 
50 
Reverse TCACCATAGAGTGCTTCCAAC 
HLCS 
Forward TGAGACCTGATCCTTAACTTCC 
50 
Reverse ATGGAAGATAGACTCCACAT 
GAPDH 
Forward TCCACTGGCGTCTTCACC 
50 
Reverse GGCAGAGATGATGACCCTTT 
 
c-Myc= v-Myc Avian Myelocytomatosis Viral Oncogene Homolog (NCBI Reference 
Sequence: NM_002467.4); COX-2= Cyclooxygenase 2 (NCBI Reference Sequence: 
NM_000963.2); HLCS= Holocarboxylase Synthetase (NCBI Reference Sequence: 
NM_000411.6); GAPDH= Glyceraldehyde-3-phosphate Dehydrogenase (NCBI 
Reference Sequence: NM_002046.4). 
 
 
Table 2 Human primers used for PCR amplification and Site-
directed mutagenesis (SDM) 
 
Plasmid 
 
Primer Sequence (5’-3’) 
Restriction 
enzyme sites Ta (oC) 
His-MBP1 
Forward TTCGGGTAGTGGAAAACCAG Bamh1 58 
Reverse CAGCAGCTCGAATTTCTTCC Sal1  
Flag-MBP-WT 
Forward ACAGGCTTCCATTGACCAG EcoRI 55.5 
Reverse TCACCATAGAGTGCTTCCAAC KpnI  
MBP-1R10,R12 
Forward ACAGGCTTCCATTGACCAG EcoRI 55.5 
Reverse TCACCATAGAGTGCTTCCAAC KpnI  
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Table 2 Primers used Site-directed mutagenesis (SDM) 
 
Plasmid   Primer Sequence (5’-3’) 
ENO1_Mut 
Forward ATG GAA CAG AAA ATA GAT CTA GGT TTG GTG CGA ACG C 
Reverse GCG TTC GCA CCA AAC CTA GAT CTA TTT TCT GTT CCA T 
 
Annotation: IEMDGTENKSK mutated to IEMDGTENRSR 
 
